Furthermore, alpha-1-antitrypsin hinders these neuroinflammatory effects in a time-dependent manner suggesting that it may be a pharmacological target for Alzheimer’s disease treatment. This evidence concerns the gene SERPINA1 and early-onset autosomal dominant Alzheimer disease.